New treatment for brucellosis

Key points
- Concepcion Lecaroz, a researcher from the University of Navarra, has developed a new therapy against brucellosis.
- This research project forms part of her doctoral thesis, defended at the University's School of Pharmacy.
- This study has permitted the development of a new treatment which significantly reduces infections in mice, as opposed to the traditional treatment with "free" (unencapsulated) antibiotics with short treatment times.
- Despite the fact that brucellosis is highly susceptible to the majority of antibiotics, the indices of relapse in humans ranges from 5 to 15% depending on the antibiotic regimen; in any case, standard treatment requires combined therapy during long periods of time.
Concepcion Lecaroz, a researcher from the University of Navarra, has developed a new therapy against brucellosis. This zoonosis - a disease or infection of animals which can be transmitted to humans under natural conditions - annually affects 500,000 people worldwide.
This research project forms part of her doctoral thesis, defended at the University's School of Pharmacy.
This study has permitted the development of a new treatment which significantly reduces infections in mice, as opposed to the traditional treatment with "free" (unencapsulated) antibiotics with short treatment times.
Despite the fact that brucellosis is highly susceptible to the majority of antibiotics, the indices of relapse in humans ranges from 5 to 15% depending on the antibiotic regimen; in any case, standard treatment requires combined therapy during long periods of time.
The alternative treatment developed by Ms. Leca'roz involves the transportation of the antibiotic gentamicina to infected cells by means of biodegradable particles, which can produce a much higher concentration of antibiotic precisely in the organs which are infected. These biodegradable systems are designed in such a way that they release the antibiotic in a controlled manner, which allows therapeutic levels of antibiotics after a reduced number of dosages.
In this research project, Concepcion Lecaroz has achieved a significant reduction of spleen pathogens in mice, which has led to the possibility of achieving similar results in humans.
In Spain, along with tuberculosis and meningococcal meningitis, brucellosis is one of the most frequent endemic bacterial pathologies. The characteristic symptoms of the disease are fever, chills, weakness, muscular pain, sweating and headaches. If the bacteria invades the bloodstream, it can infect numerous tissues and organs, such as the liver, the spleen, the bones, the genitourinary system, the lungs, the central nervous system, and the heart, to the point of even endangering the life of the patient.
http://www.basqueresearch.com/
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsAdding blood pressure drug to standard antibiotics speeds up TB treatment
Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard,…
30 August 2013
NewsNew hope for improved TB treatments
Researchers at the University of Southampton have identified new markers of tuberculosis (TB) that may help in the development of new diagnostic tests and treatments. Published online in the Journal of Infectious…
12 August 2013
NewsHIV treatment adherence and outcomes improving among HIV-positive transgender people
HIV-positive transgender people are just as likely to stay in care, take their medication and have similar outcomes as other men and women living with the disease, according to new research from the Perelman School of…

